A Designated Medical Event, or DME, is a medical condition listed by the European Medicines Agency that receives particular priority in the review of suspected adverse drug reaction reports due to its medical severity and frequent drug relatedness. The DME list serves as a tool for daily pharmacovigilance to prioritize the review of suspected adverse reactions. It is not a catalog of confirmed drug effects and does not automatically assign causality to an individual report.<\/p>\n
The list uses MedDRA Preferred Terms and is provided by the EMA within the European medicines regulatory network. Its function is practical: reports of these events should not be deprioritized in safety monitoring simply because a statistical prioritization rule does not trigger. A DME draws attention to the medical significance of a case, for example, a rare severe syndrome whose early detection can be relevant for patient protection and product information.<\/p>\n
Before classifying a case, however, diagnosis, exposure, time course, comorbidities, concomitant medication, and alternative causes must be examined. The MedDRA term must accurately correspond to the clinical finding; imprecise coding can set false priorities as well as conceal relevant cases. DME listing does not replace follow-up, medical causality assessment, or documentation of why a particular case was further analyzed or excluded.<\/p>\n
In signal management, DMEs are a tool for signal detection and case prioritization. The EMA states that they warrant special attention regardless of statistical criteria for prioritizing safety reviews. This does not imply a predetermined outcome: a DME report may lead to signal validation, but it may also prove insufficiently substantiated after individual case review. The decision remains dependent on data quality and the context of the respective drug-event combination.<\/p>\n
The cross-product list facilitates a standardized initial screening, but it does not replace a product-specific safety strategy. A DME may be highly relevant for one active substance but represent a plausible complication of an underlying disease for another. Therefore, background incidence, approved population, and known risks must always be considered. The list guides attention, not the final regulatory conclusion.<\/p>\n
Designated Medical Events are not to be equated with Important Medical Events. Important Medical Events are used in assessing whether a specific case should be classified as serious; the DME list, in contrast, is a prioritization tool for safety monitoring. Therefore, an event being on a list does not automatically answer the question of the seriousness of an individually reported case.<\/p>\n
A further distinction exists from an Adverse Event of Special Interest (AESI): an AESI is defined by the sponsor for a specific study program or product, for example, due to mechanism of action, target population, or known class effects. The EMA DME list is established by the authorities and is not considered a study-specific monitoring plan. An event can be both an AESI and a DME, but the two classifications are based on different purposes.<\/p>\n
The DME list should not be read as a static clinical diagnostic rule. It is published within the framework of European drug safety and uses standardized MedDRA terms to enable consistent database queries. When applying it, however, the specific version of the list must be checked. Otherwise, a historical data extract and a current safety review may yield different hit sets. For audits, it is helpful to separately document the list version used, the query time, and the medical assessment of the hits. This demonstrates that the list provides a systematic pre-sorting, not a substitute for individual case assessment.<\/p>\n
For internal product safety reviews, DME queries can be combined with other sorting criteria, such as novelty, case completeness, or an unfavorable outcome. The DME characteristic should remain visible as a separate parameter. Otherwise, it will not be possible to verify later whether the regulatory-intended prioritization impulse was actually incorporated into case processing.<\/p>\n
In studies, the DME logic enables additional medical review of serious or unusual reports before a statistical accumulation becomes apparent. Safety lists should therefore consistently identify MedDRA Preferred Terms and, for a DME, particularly check the completeness of diagnostic findings, outcome, and temporal drug exposure. In blinded studies, it must be ensured that the safety assessment does not unnecessarily compromise the integrity of the blinding.<\/p>\n
Full-service CROs like Mediconomics provide support through quality-assured coding, DME-supported review lists, targeted queries to study sites, and medical case summaries. They ensure that a report identified as a DME reaches the responsible safety roles and that further assessment is cleanly documented within the regular SAE workflow.<\/p>\n
Is a DME always a serious adverse reaction?<\/strong><\/p>\n No. The DME list prioritizes safety review; the seriousness of an individual case is assessed separately based on relevant criteria.<\/p>\n Does the DME list replace a disproportionality analysis?<\/strong><\/p>\n No. It complements statistical methods because DMEs receive special attention independently of their thresholds.<\/p>\n Can a sponsor define their own DMEs?<\/strong><\/p>\n No. DME refers to the EMA list; for product-specific events of interest, a sponsor uses the AESI concept.<\/p>\n A Designated Medical Event, or DME, is a medical condition listed by the European Medicines Agency that receives particular priority in the review of suspected adverse drug reaction reports due to its medical severity and frequent drug relatedness. The DME list serves as a tool for daily pharmacovigilance to prioritize the review of suspected adverse […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[23],"class_list":["post-8078","glossary","type-glossary","status-publish","hentry","glossary-cat-pharmakovigilanz"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8078\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8078"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n